Technical Data
M2750-11A
MCP2, Recombinant, Human (Macrophage/Monocyte Chemotactic Protein 2, Chemokine C-C Motif Ligand 8, CCL8, HC14, Monocyte Chemotactic Protein 2, Small Inducible Cytokine A8 Precursor, SCYA8, SCYA10)
2ug
10ug
Molecular Biology Storage: -20CShipping: RT
Recombinant Human MCP-2 is a non-glycosylated, polypeptide chain containing 76 amino acids and having a molecular mass of 8904 Dalton.

Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be Gln-Pro-Asp-Ser-Val.

Dimers and Aggregates:
1% as determined by silver-stained SDS-PAGE gel analysis.

Biological Activity:
MCP-2 is fully biologically active when compared to standard. The specific activity as determined by the ability of MCP-2 to chemoattract human peripheral blood at 10-100ng/ml.

Endotoxin:
0.1ng/ug (IEU/ug) of Murine Monocyte Chemotactic Protein-2.

Protein Content:
Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280nm.
2. Analysis by RP-HPLC, using a calibrated solution of Human MCP-2 as a Reference Standard.

Reconstitution:
Reconstitute the lyophilized MCP-2 in sterile 18MO-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.

Storage and Stability:
Lyophilized powder may be stored at 4C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.
Source: E. coli
Purity: 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.
Concentration: ~0.1mg/ml
Form: Supplied as a lyophilized powder. No additives.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hellier S, Frodsham AJ, Klenerman P, Wright M, Hepatology 2003 Dec;38(6):1468-76 2. Expression of the chemokines, monocyte chemotactic protein (MCP)-1 and MCP-2 in endometrium of normal women and Norplant users, does not support a central role in macrophage infiltration into endometrium. Hampton AL, Rogers PA, Salamonsen LA, J Reprod Immunol 2001 Feb;49(2):115-32 3. Cloning of equine chemokines eotaxin, monocyte chemoattractant protein (MCP)-1, MCP-2 and MCP-4, mRNA expression in tissues and induction by IL-4 in dermal fibroblasts. Benarafa C, Cunningham FM, Horohov DW, Vet Immunol Immunopathol 2000 Oct 31;76(3-4):283-98 4. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Van den Steen PE, Proost P, Van Damme J, Blood 2000 Oct 15;96(8):2673-81 5. Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells. Modulation by corticosteroids and T-helper 2 cytokines. Pype JL, Dupont LJ, Van Coillie E, Demedts MG, Am J Respir Cell Mol Biol 1999 Oct;21(4):528-36 6. Transcriptional control of the human MCP-2 gene promoter by IFN-gamma and IL-1beta in connective tissue cells. Van Coillie E, Van Aelst I, Billiau A, J Leukoc Biol 1999 Sep;66(3):502-11.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.